SCNX Stock Catalyst: Scienture Holdings Announces Commercial Launch and Initial Orders for REZENOPY™

Aug 12, 2026 · 8:04am ET

The highest dose FDA-approved Naloxone Nasal Spray.

Max move

+46.5%

High of day $0.60

Sparker timei

8:04am ET

SCNX · Aug 12, 2026

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Scienture Holdings, Inc. (Nasdaq: SCNX) announced the commercial launch and fulfillment of initial purchase orders for REZENOPY™, its highest dose FDA-approved Naloxone Nasal Spray. The announcement was made following the product's regulatory approval.

REZENOPY™ is now available for commercial distribution, with initial orders already being fulfilled. The product is designed to address opioid overdose emergencies.

Scienture Holdings has a free float of 7,919,732 shares.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time SCNX sparks.

Download Sniper App →

Catch the next SCNX-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →